Oragenics Inc represents values of innovation, excellence, and integrity. With a strong corporate philosophy, the company aims to revolutionize the field of oral health through cutting-edge technologies and research. Oragenics is committed to improving the lives of individuals by developing novel therapeutic solutions to combat oral diseases, such as oral mucositis and dental caries. By prioritizing scientific advancements and maintaining high ethical standards, Oragenics Inc continually strives to provide effective and safe treatments for better global oral healthcare.

Oragenics Inc is primarily present in the United States.

Oragenics Inc, a leading biopharmaceutical company, has achieved several significant milestones. The company successfully completed the Phase 2 clinical trial for its lead product candidate, AG013, which demonstrated promising efficacy in treating oral mucositis, a severe side effect of cancer therapy. Additionally, Oragenics Inc entered into a collaboration agreement with the University of Florida to advance the development of lantibiotics, a novel class of antibiotics. The company also expanded its intellectual property portfolio, securing key patents for its technology platforms. With these achievements, Oragenics Inc is poised to make further advancements in the field of biopharmaceuticals, enhancing its position in the market.

Oragenics Inc is a biopharmaceutical company with a rich history and background in developing innovative therapies for infectious diseases. Founded in 1996, the company has been committed to advancing their proprietary technology platforms, including their patented TerraCoV2 vaccine construct, which aims to combat COVID-19. Oragenics Inc has also focused on addressing oral health problems through its mutanobactin-based antibiotics. With a strong emphasis on research and development, the company continues to pursue groundbreaking solutions to global health issues. Oragenics Inc's dedication to scientific excellence and groundbreaking technologies has positioned them as a leading player in the biopharmaceutical industry.

The main competitors of Oragenics Inc in the market include pharmaceutical companies such as Procter & Gamble, Pfizer, and Johnson & Johnson.

Oragenics Inc is primarily active in the biotechnology and life sciences industry.

The business model of Oragenics Inc. revolves around the development and commercialization of innovative therapies and probiotics for several medical conditions. The company focuses on utilizing its core technology, known as lantibiotics, to target harmful pathogens and bacteria. Oragenics Inc. aims to provide effective solutions for infectious diseases, oral health, and other related issues. By leveraging their scientific expertise and research capabilities, the company continually strives to improve patient outcomes and build long-term value for its stakeholders.

Det Oragenics P/E-forhold er -0,65.

Oragenics KUV er 0.

AlleAktien Kvalitetsscore for Oragenics er 1/10.

Omsætningen kan i øjeblikket ikke beregnes for Oragenics.

Den forventede Oragenics indtjening er -1,45 mio. USD.

Oragenics Inc is a biopharmaceutical company specializing in the discovery, development, and marketing of products for the treatment of infectious and autoimmune diseases. The company is listed on the NYSE American under the ticker symbol "OGEN" and is headquartered in Tampa, Florida, USA. Oragenics operates through two core business segments: antibiotic development and probiotic therapeutics. Oragenics' antibiotic business focuses on the development of treatments for infections, particularly those caused by resistant bacterial strains. The company has developed proprietary technologies to support the identification and optimization of antibiotic candidates. Recently, the company entered into an exclusive license agreement with the National Research Council of Canada for the use of bacteriophages in the treatment of lung infections. The company has various products in different stages of clinical development in this segment. Probiotic therapeutics are used for the treatment of autoimmune diseases. Oragenics develops therapies based on bacterial strains derived from healthy oral flora. The company also offers services for the characterization of oral bacterial strains. Oragenics is currently primarily focused on the development of Lahzelimab (OG716), an anti-CD3 antibody therapy used for the treatment of inflammatory bowel disease (IBD). Lahzelimab has been designed to target the underlying cause of the disease by reducing excessive activation of the immune system. Oragenics also has a subsidiary, Noachis Terra Inc., which specializes in the production of natural bio-aggregates that can be used in scientific biotechnology applications. By utilizing Noachis Terra, Oragenics can employ cost-effective production methods to develop potentially valuable technologies and therapeutics. Oragenics' business model is based on identifying unmet medical needs and utilizing expertise in the discovery and development of therapies to address these needs. The company strategically targets markets with strong demand and promising investments in research and development. It is noteworthy that Oragenics develops technologies based on natural microbial diversity, allowing for the development of potential therapies that traditional chemicals cannot achieve. Oragenics focuses on developing groundbreaking therapeutics to address significant health issues. Close collaboration between the research and development department and the clinical department allows Oragenics to gain important insights from ongoing clinical studies and respond quickly to changing circumstances or discoveries. In summary, Oragenics aims to develop innovative therapies based on human microbial diversity that lead to a significant improvement in the quality of life and health of patients.

Oragenics udbetaler et udbytte på 0 USD fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for Oragenics, eller selskabet udbetaler ikke udbytte.

ISIN'en for Oragenics er US6840233026.

WKN for Oragenics er A2JBK2.

Tickeren for Oragenics er OGEN.

I løbet af de sidste 12 måneder betalte Oragenics en dividende på . Dette svarer til et dividendeudbytte på omkring . For de kommende 12 måneder vil Oragenics sandsynligvis betale en dividende på 0 USD.

Udbytteafkastet for Oragenics er i øjeblikket .

Oragenics betaler kvartalsvis udbytte. Dette uddeles i månederne .

Oragenics betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0 USD. Dette svarer til et dividendeafkast på 0 %.

Oragenics bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på Oragenics fra den 6.10.2024 på 0 USD, skulle du have haft aktien i din portefølje før ex-datoen den 6.10.2024.

Udbetalingen af det sidste udbytte blev foretaget den 6.10.2024.

I løbet af 2023 udbetalte Oragenics 0 USD i form af dividender.

Udbytterne fra Oragenics udbetales i USD.